Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2021 | Treating cancer during the COVID-19 pandemic

Federico Cappuzzo • 22 Mar 2021
ELCC 2021
Breast Cancer General Antibodies Canakinumab

Federico Cappuzzo, MD, PhD, AUSL della Romagna, Ravenna, Italy, talks on the risks of COVID-19 infections in patients with cancer, outlining the implications of delayed treatment and steps being taken to mitigate infection risks. Dr Cappuzzo also highlights data from a study investigating the efficacy of canakinumab and a study of the COVID-19 risk in patients with breast cancer who are receiving CDK4/6 inhibitors. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.

More from Federico Cappuzzo

Current treatment recommendations and future directions for EGFR-mutant NSCLC
1:25
Current treatment recommendations and future directions for EGFR-mutant NSCLC
Federico Cappuzzo • 7 Aug 2022
FoRT 05-BEAT: comparing 1L atezolizumab vs atezolizumab + bevacizumab in PD-L1 high NSCLC
1:06
FoRT 05-BEAT: comparing 1L atezolizumab vs atezolizumab + bevacizumab in PD-L1 high NSCLC
Federico Cappuzzo • 7 Aug 2022
MRD status in lung cancer
1:18
MRD status in lung cancer
Federico Cappuzzo • 7 Aug 2022
METROS: crizotinib in ROS1+NSCLC long-term OS analysis in patients with brain metastasis
1:06
METROS: crizotinib in ROS1+NSCLC long-term OS analysis in patients with brain metastasis
Federico Cappuzzo • 7 Aug 2022

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals